Objectives: Substantial evidence showing an association between type 2 diabetes (T2D) and cerebral atrophy, cognitive impairment, and dementia is accumulating. However, relatively little is known about the subclinical effects of high plasma glucose levels within the normal range. The aim of this study was to investigate the association between plasma glucose levels and hippocampal and amygdalar atrophy in a sample of 266 cognitively healthy individuals free of T2D, aged 60-64 years, taking part in a longitudinal study of aging.
There is an increasing research focus on type 2 diabetes (T2D) as a risk factor for brain aging, cognitive decline, and dementia. 1, 2 Other factors associated with diabetes, such as caloric intake, body weight, and insulin resistance have also been shown to be independently associated with increased risk of age-related cognitive decline. [3] [4] [5] However, it is not clear whether high plasma glucose levels in the normal range are also harmful to brain health.
In nondiabetic individuals, experimentally raised plasma glucose levels have been found to be associated with increased systemic inflammation. 6 Because chronic systemic inflammation has been shown to be associated with cerebral atrophy, particularly in the hippocampus, it is possible that consistently higher glucose levels within the normal range may be associated with neurodegeneration. In addition, excessive coagulation function activity, which potentiates inflammatory processes, 7 can also be caused by poorly regulated plasma glucose levels. 8 Higher glucose levels are therefore likely to raise the risk of thrombosis, microemboli, and clinical and subclinical strokes, which are risk factors for brain aging, 9 and, in particular, for hippocampal integrity because this structure is more sensitive to hypoperfusion and environmental stressors. 10 Importantly, higher glucose levels in nondiabetic individuals have been shown to be associated with poorer memory performance. 11 The aim of this study was, therefore, to investigate in cognitively healthy individuals, who did not have T2D, whether higher fasting plasma glucose levels falling in the normal range as defined by the World Health Organization were associated with declines in hippocampal and amygdalar volumes.
METHODS Study population. The PATH Through Life
Study has been described elsewhere 12 as has its MRI substudy. 13 In brief, participants (60 -64 years) who were residents of the cities of Canberra and Queanbeyan, Australia, were recruited randomly through the electoral roll to participate in a longitudinal study of aging. Enrollment to vote is compulsory for Australian citizens. A total of 2,551 participants were included at baseline (2001), representing a 58.3% response rate. Of those, 2,076 agreed to be contacted regarding MRI assessment, 622 randomly selected participants were offered a scan, and 479 completed a structural MRI scan. Of those, 431 underwent an MRI scan at wave 2 (2005) and after exclusion of participants with neurologic disorders, stroke, MRI images of poor quality, and missing APOE*E4 genotype data, 308 participants were available for longitudinal analyses. An additional 26 were excluded because they had T2D, a further 16 because their glucose level was higher than 6.1 mmol/L (110 mg/dL), and another 17 for taking anxiety/depression medication, leaving 249 for consideration in the present investigation (figure 1).
Standard protocol approvals, registrations, and patient consents.
The study was approved by the Australian National University Ethics Committee, and all participants provided written informed consent.
Sociodemographic and health measures. Total years of education, stroke, depression medication, and smoking were assessed by self-report. Blood pressure was measured twice with the participant seated after a rest of at least 5 minutes. Participants were classified as hypertensive if their systolic or diastolic blood pressure measures averaged over 2 readings were higher than 90 and 140 mm Hg, respectively, or if they took antihypertensive medication. APOE*E4 genotype was determined from DNA collected by cheek swab. Alcohol intake was assessed with the Alcohol Use Disorders Identification Test. 14 
Diabetes, plasma glucose, and body mass index measures.
Participants were considered to have diabetes if they reported having diabetes or were receiving drug treatment or consuming a special diet for diabetes, or if their fasting glucose plasma level was Ն10 mmol/L. Venous blood was collected after an overnight fast of at least 10 hours. Plasma and serum aliquots were frozen at Ϫ80°C. Plasma glucose was measured on an LX20 analyzer by an oxygen rate method (Beckman-Coulter, Fullerton, CA). Body mass index (BMI) was computed with the formula weight (kg)/height (m 2 ) based on self-reports of weight and height. interest (ROI) on each slice of a T1-weighted scan in coronal orientation using Analyze 5.0 (Brain Imaging Resource, Mayo Clinic, Rochester, MI). The outlining of the hippocampus and amygdala always proceeded from anterior to posterior and was traced according to the protocol outlined by Watson et al. 15 with a modification suggested by Brierly et al. 16 Volume estimations were repeated on 10 randomly selected scans, and interclass correlations between raters was in excess of 0.95 for all structures. 17, 18 Intracranial volume (ICV) was computed with the Freesurfer/FSL package (http://surfer.nmr.mgh.harvard.edu) for wave 1 and wave 2 images.
Statistical analysis. Descriptive analyses were conducted using 2 tests for categorical data and t tests to compare groups on continuous variables. Hippocampal and amygdalar volumes were normalized for ICV using the formula adjusted volume ϭ raw volume Ϫ b ϫ (ICV Ϫ mean ICV), where b is the slope of regression of an ROI volume on ICV. Associations between plasma glucose levels and hippocampal and amygdalar volumes and atrophy were investigated using general linear models (GLMs) while controlling for sex, age, APOE*E4 genotype, hypertension, BMI, and smoking. Hippocampal and amygdalar atrophy was assessed by using the wave 2 volume as the dependent variable and controlling for wave 1 volume as the covariate in the analyses while also controlling for elapsed time between assessments. In addition, because the image acquisitions were different between waves, the difference in ICV between wave 1 and wave 2 was also controlled for by entering it as a covariate in the analyses, an approach already applied elsewhere. 18 Interactions between plasma glucose levels, sex, and APOE*E4 genotype were also tested. ␣ was set at 0.01.
RESULTS
Participants were on average 62.6 years (range 60 -65 years; SD 1.39) at wave 1 with a mean follow-up of 4 years (SD 0.21). The participants' demographic and health measures are presented in table 1 (see table e-1 on the Neurology ® Web site at www.neurology.org for brain measures and table e-2 for comparisons of demographic characteristics with those of the original cohort). Fasting plasma glucose ranged from 3.2 to 6.0 mmol/L (mean 4.93 mmol/L, SD 0.59). Because intracranial volumes at wave 1 and wave 2 differed, with the wave 2 volume being slightly (2.7%) but significantly smaller, t(332) ϭ 8.185, p Ͻ 0.001, the possible impact of ICV differences was further investigated with correlational analyses (not shown), which demonstrated that the difference in ICV between wave 1 and 2 explained less than 1.5% of the variance in ROI volume change. Table 2 presents results from the GLM analyses investigating the association between plasma glucose and ROI volume at wave 1 or atrophy over 4 years after controlling for sex, age, education, APOE*E4 genotype, hypertension, alcohol intake, BMI, and smoking. Atrophy was assessed by controlling for wave 1 volume and time between wave 1 and wave 2 assessments while predicting wave 2 volume. These analyses showed that plasma glucose was not associated with baseline ROI volumes in cross-sectional analyses. In contrast, plasma glucose levels were negatively associated with left and right hippocampal and amygdalar volumes at wave 2 after controlling for wave 1 volumes, indicating that higher glucose was associated with greater atrophy. None of the gender or APOE*E4 interactions reached significance.
Scatter plots of the associations between ROI atrophy over 4 years and fasting plasma glucose levels are presented in figure 2.
Sensitivity analyses. Because the American Diabetes Association recommends more stringent norms than the World Health Organization for fasting plasma glucose, we recomputed all analyses after excluding participants with a fasting plasma glucose level higher than 5.6 mmol/L (100 mg/dL) (mean 4.83 mmol/L, range 3.2Ϫ5.6 mmol/L, SD 0.53, n ϭ 225). Results followed a pattern identical to those presented above (table e-3) .
To further investigate whether plasma glucose effects might be modulated by diabetes or insulin resistance comorbidity, analyses with all participants (n ϭ 283), including those with T2D or glucose levels higher than 6.1 mmol/L were repeated. Again, results followed a similar pattern (table e-4).
Finally, because the effect of BMI, although controlled for in the analyses, may make the interpretation of results more difficult, another set of analyses were computed (n ϭ 94) after exclusion of individuals with a BMI outside the normal range (Ͼ25 kg/ m 2 ). Findings were essentially the same as above (table e-5).
DISCUSSION
This study's main findings were that baseline fasting plasma glucose levels in the normal range in a large sample of community-dwelling indi- Table 1 Participants' demographic and health characteristics viduals in their 60s were significantly and positively associated with hippocampal and amygdalar atrophy over 4 years. Moreover, a number of factors make these results unique. First, participants who undertook neuroimaging assessment were randomly selected from a larger cohort randomly selected from the population, thus ensuring the representativeness of the sample. Second, individuals with diabetes or subclinical plasma glucose levels were excluded. The glucose level threshold used for exclusion was based on the World Health Organization threshold for impaired fasting hyperglycemia (6.1 mmol/L, 110 mg/ dL) to avoid the inclusion of participants with subclinical diabetes or glucose intolerance. Third, individuals with neurologic disorders or those taking antidepressive medication were excluded to limit the possibility that other, unrelated deficits might produce the effects detected. Finally, a longitudinal design in a narrow age cohort was used while controlling for important covariates to ensure that, short of a randomized controlled trial (which would be unethical in this context), a convincing link between plasma glucose and medial temporal lobe atrophy could be detected if present. It should also be noted that the rate of hippocampal atrophy (2% per annum) and the average plasma glucose level (4.92 mmol/L) detected in this sample were consistent with those reported in the literature when the age range and exclusion criteria were considered. 19, 20 Given the robust prospective nature of this investigation and the detailed conservative controls undertaken, the present findings strongly suggest that higher glucose levels within what is considered the normal range are associated with greater hippocampal and amygdalar atrophy. Although we are unaware of any other study showing such an association in individuals without diabetes, glucose intolerance, or the metabolic syndrome (MetS), these results are consistent with the animal literature and studies investigating cognitive change in humans.
Specifically, rats exposed to a neurotoxic compound (kainic acid) who had higher plasma glucose levels were more susceptible to hippocampal neuronal loss than those with a lower glucose levels. 21 In another study, rats exposed to a prolonged highfructose diet had decreased neurogenesis. 22 Significantly, rats fed a high-glucose diet who had elevated fasting glucose exhibited impaired spatial learning, reduced hippocampal dendritic spine density, and reduced long-term potentiation. 23 In humans, a large study of 46,578 individuals with fasting glucose levels lower than 5.6 mmol/L (100 mg/dL) showed that higher plasma glucose levels within the normal range were associated with an increased risk of developing T2D (6% per additional Table 2 Glucose level as predictor of hippocampal and amygdalar volume at wave 1 and of atrophy over 4 years (n After normalization for intracranial volume. c Controlled for sex, age, wave 1 to wave 2 intracranial volume difference, APOE*E4 genotype, hypertension, alcohol intake, BMI, smoking, elapsed time between assessment, and baseline volume; atrophy in model is assessed by controlling for baseline hippocampal or amygdalar volume; therefore, a positive association reflects less atrophy. d Harmful vs light intake.
1 mg/dL). 24 Furthermore, in another study, higher glucose levels in individuals free of T2D were associated with poorer memory performance. 11 Indirect evidence supporting the benefits of lower cerebral glucose levels is also available in studies demonstrating the protective effect of insulin on the CNS. 25 Interestingly, consistent with previous findings, results of the present investigation clearly show that plasma glucose effects (accounting for 6%-10% of atrophy) are not uniquely due to preclinical states or preexisting individual differences in brain structure. Although the main analyses used widely accepted cutoffs, subanalyses using even tighter inclusion criteria for fasting glucose (Ͻ5.6 mmol/L) and for BMI (Ͻ25 kg/m 2 ) produced essentially identical findings or, in the case of BMI, slightly stronger findings. This result suggests that the effect of plasma glucose on cerebral structural integrity is not restricted to the upper normal range. Moreover, plasma glucose levels were not significantly associated with baseline volumes, which indicates that preexisting differences in cerebral structure are not likely to be the cause of the detected effects.
Although not the focus of this investigation, it is important to consider which mechanisms might underlie the association between plasma glucose levels and neurodegeneration. Support for the involvement of inflammatory processes is available from a study which found that experimentally raised plasma glucose levels were associated with increased plasma cytokine levels (tumor necrosis factor-␣, interleukin-6, and interleukin-10), both in healthy control subjects and in individuals with impaired glucose tolerance (IGT). 6 However, inflammatory reactions peaked higher and lasted longer in subjects with IGT. These findings indicate that control of plasma glucose levels modulates systemic inflammatory responses and that individuals with T2D are more likely to be exposed to longer lasting and stronger inflammatory states. Because chronic systemic inflammation has been shown to be associated with cerebral atrophy, particularly in the hippocampus, it is likely that consistently higher glucose levels within the normal range may be associated with neurodegeneration. However, such an effect could also be produced by comorbid conditions. An investigation of nonobese first-degree relatives of individuals with T2D who are known to be at higher risk of developing the disease found that they did not have higher C-reactive protein (CRP) levels despite having a lower insulin sensitivity measure. 26 In contrast, CRP levels were strongly associated with fat mass. These results could Associations between hippocampal and amygdalar atrophy over 4 years and fasting plasma glucose suggest that adiposity rather than high glucose levels might increase systemic inflammation. For this reason, in our analyses we carefully controlled for BMI and performed sensitivity analyses to exclude the possibility that the effects detected were due to fat mass rather than to glucose levels. Other important comorbid conditions or known risk factors such as hypertension, medication for anxiety and depression, APOE genotype, and smoking were also controlled for. In addition to inflammation, coagulation-related abnormalities have been identified in T2D. Tissue factor, factor VII, (pro-)thrombin, and fibrinogen levels are raised in T2D. 27 These alterations have been shown to lead to abnormal clotting and greater risk of a cardiovascular event. Activation of prothrombic pathways has also been shown to be caused by poorly regulated plasma glucose levels in prediabetic states such as insulin resistance and MetS. 9 For example, induced hyperglycemia in healthy volunteers was associated with a dramatic increase in tissue factor procoagulant activity, as well as with increases in other prothrombic factors and platelet activation. 8 Because prediabetic states such as MetS and insulin resistance have been associated with increased risk of thrombosis 28 it is possible that high glucose levels in the absence of T2D may also lead to an abnormal coagulation function, thus increasing the likelihood of thrombosis, microemboli, and clinical and subclinical strokes, which are risk factors for brain aging. Moreover, interactions between the coagulation and inflammatory pathways whereby inflammation leads to activation of coagulation and coagulation also considerably affects inflammatory activity have been documented. This synergy is likely to further amplify the effect of discrete risk factors such as glucose levels. 7 Psychological stressors are also associated with an increased risk of T2D. Individuals with depression have been found in a recent meta-analysis to have a 60% higher risk of developing diabetes. 29 Because chronic stress is associated with increased activation of the hypothalamic-pituitary-adrenal (HPA) axis and because HPA activation has been found to be associated with increased glucose levels, 30 it is possible that stressors may contribute to higher glucose levels and their effects on the brain.
There is now strong evidence that chronic increases in inflammatory responses, high stress hormone levels, and abnormal blood coagulation activation are linked to cerebral changes and associated decreases in cognitive function. Neurogenesis has been shown to be impaired in the hippocampus by inflammatory cytokines and activation of the HPA axis. [31] [32] [33] A recent meta-analysis of human in vivo studies also found that individuals exposed to traumatic events with and without posttrau-matic stress disorder had smaller hippocampal volumes. 34 Furthermore, chronic stress has been found to be associated with hippocampal and amygdalar atrophy, 35, 36 and individuals with T2D present with smaller cerebral volumes and greater atrophy rates across the brain and specifically in the medial temporal lobe. [37] [38] [39] [40] Consequently, the present results are consistent with and contribute to a body of convergent evidence, which convincingly suggests that higher plasma glucose levels, even within what is considered the normal range, are associated with compromised cerebral integrity irrespective of other comorbidities.
This study has some limitations but also significant strengths. Although the subsample of individuals used for neuroimaging analyses was randomly sampled from a larger cohort, which itself was randomly sampled from the community, it may not be completely representative of the population at large. It also lacks ethnic diversity. MRI scans were collected with a somewhat different protocol at wave 2 to improve image quality, and this may have introduced some measurement error. However, analyses showed that this effect explains less than 1.5% of the variance in medial temporal lobe volume change and was controlled for in all analyses. A previous investigation also showed that this difference in intracranial volume was not greater than that observed between software packages on identical scans. 18 In contrast, this research was conducted in a large sample that is more representative than many described in the literature, which are often composed of self-selected volunteers or patients. This afforded good statistical power, which allowed analyses that controlled for important covariates but may not have been sufficient to detect subtle interactions. Although the narrow cohort design means the results cannot be generalized to older samples, it is more likely to reduce cohort effects and to minimize the influence of age-related differences in biological processes that are more likely in broader age groups.
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